10/16/2013

The cholesterol drug candidate alirocumab has shown promise in its first Phase III trial, Regeneron Pharmaceuticals and Sanofi are set to announce today. The lipid drug is the first to reach late-stage studies in a class of PCSK9 inhibitors also being developed by Pfizer and Amgen.

Related Summaries